183 related articles for article (PubMed ID: 37087499)
1. NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression.
Sim N; Li Y
Commun Biol; 2023 Apr; 6(1):445. PubMed ID: 37087499
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1.
Xu X; Li Y; Bharath SR; Ozturk MB; Bowler MW; Loo BZL; Tergaonkar V; Song H
Nat Commun; 2018 Aug; 9(1):3183. PubMed ID: 30093619
[TBL] [Abstract][Full Text] [Related]
3. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.
Li Y; Zhou QL; Sun W; Chandrasekharan P; Cheng HS; Ying Z; Lakshmanan M; Raju A; Tenen DG; Cheng SY; Chuang KH; Li J; Prabhakar S; Li M; Tergaonkar V
Nat Cell Biol; 2015 Oct; 17(10):1327-38. PubMed ID: 26389665
[TBL] [Abstract][Full Text] [Related]
4. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.
Ang DA; Carter JM; Deka K; Tan JHL; Zhou J; Chen Q; Chng WJ; Harmston N; Li Y
Nat Commun; 2024 Mar; 15(1):2513. PubMed ID: 38514625
[TBL] [Abstract][Full Text] [Related]
5. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.
de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C
Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling.
Cherry EM; Lee DW; Jung JU; Sitcheran R
Mol Cancer; 2015 Jan; 14(1):9. PubMed ID: 25622756
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA PAXIP1-AS1 facilitates cell invasion and angiogenesis of glioma by recruiting transcription factor ETS1 to upregulate KIF14 expression.
Xu H; Zhao G; Zhang Y; Jiang H; Wang W; Zhao D; Yu H; Qi L
J Exp Clin Cancer Res; 2019 Dec; 38(1):486. PubMed ID: 31823805
[TBL] [Abstract][Full Text] [Related]
8. Role for protein kinase Ctheta (PKCtheta) in TCR/CD28-mediated signaling through the canonical but not the non-canonical pathway for NF-kappaB activation.
Li Y; Sedwick CE; Hu J; Altman A
J Biol Chem; 2005 Jan; 280(2):1217-23. PubMed ID: 15536066
[TBL] [Abstract][Full Text] [Related]
9. Alternative NF-κB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3.
Tao Y; Liu Z; Hou Y; Wang S; Liu S; Jiang Y; Tan D; Ge Q; Li C; Hu Y; Liu Z; Chen X; Wang Q; Wang M; Zhang X
Oncogene; 2018 Nov; 37(44):5887-5900. PubMed ID: 29973688
[TBL] [Abstract][Full Text] [Related]
10. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1.
Rocha S; Martin AM; Meek DW; Perkins ND
Mol Cell Biol; 2003 Jul; 23(13):4713-27. PubMed ID: 12808109
[TBL] [Abstract][Full Text] [Related]
11. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland.
Demicco EG; Kavanagh KT; Romieu-Mourez R; Wang X; Shin SR; Landesman-Bollag E; Seldin DC; Sonenshein GE
Mol Cell Biol; 2005 Nov; 25(22):10136-47. PubMed ID: 16260626
[TBL] [Abstract][Full Text] [Related]
12. c-Ets1 inhibits the interaction of NF-κB and CREB, and downregulates IL-1β-induced MUC5AC overproduction during airway inflammation.
Song KS; Yoon JH; Kim KS; Ahn DW
Mucosal Immunol; 2012 Mar; 5(2):207-15. PubMed ID: 22294049
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway.
Eliopoulos AG; Caamano JH; Flavell J; Reynolds GM; Murray PG; Poyet JL; Young LS
Oncogene; 2003 Oct; 22(48):7557-69. PubMed ID: 14576817
[TBL] [Abstract][Full Text] [Related]
14. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells.
Hatada EN; Do RK; Orlofsky A; Liou HC; Prystowsky M; MacLennan IC; Caamano J; Chen-Kiang S
J Immunol; 2003 Jul; 171(2):761-8. PubMed ID: 12847243
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
Hu J; Colburn NH
Mol Cancer Res; 2005 Feb; 3(2):100-9. PubMed ID: 15755876
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
[TBL] [Abstract][Full Text] [Related]
17. Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB.
Katoh M; Katoh M
Int J Oncol; 2009 Jun; 34(6):1737-42. PubMed ID: 19424592
[TBL] [Abstract][Full Text] [Related]
18. The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma.
Lee DW; Ramakrishnan D; Valenta J; Parney IF; Bayless KJ; Sitcheran R
PLoS One; 2013; 8(2):e57489. PubMed ID: 23451236
[TBL] [Abstract][Full Text] [Related]
19. Activation of the non-canonical NF-κB/p52 pathway in vascular endothelial cells by RANKL elicits pro-calcific signalling in co-cultured smooth muscle cells.
Harper E; Rochfort KD; Forde H; Davenport C; Smith D; Cummins PM
Cell Signal; 2018 Jul; 47():142-150. PubMed ID: 29678621
[TBL] [Abstract][Full Text] [Related]
20. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.
Lessard L; Bégin LR; Gleave ME; Mes-Masson AM; Saad F
Br J Cancer; 2005 Oct; 93(9):1019-23. PubMed ID: 16205698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
